ERBB2 and cancer: First of all, nanobodies targeting cancer-specific membrane proteins (e.g. HER2, EGFR, M-protein, CD20 and CD38) have been evaluated for both imaging and therapeutic applications 73,95,96,122,130,144,147,211.